Bio-Rad Laboratories, Inc. (NYSE: BIO-B) Stock Competitors & Peer Comparison
See BIO-B's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BIO-B and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIO-B | $355.39 | -2.41% | 9.6B | -62.58 | -$5.68 | N/A |
| ABT | $104.49 | -0.18% | 181.5B | 20.13 | $5.21 | +2.40% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $94.64 | -0.85% | 121.2B | 17.14 | $5.53 | +3.02% |
| SYK | $295.29 | +0.70% | 113B | 22.01 | $13.39 | +1.20% |
| BSX | $44.10 | -0.09% | 64.3B | 14.32 | $3.10 | N/A |
| EW | $87.35 | -0.85% | 49.9B | 32.07 | $2.70 | N/A |
| DXCM | $86.23 | -1.69% | 32.5B | 33.74 | $2.55 | N/A |
| GEHC | $69.29 | -1.51% | 31.4B | 15.26 | $4.56 | +0.20% |
| PHG | $25.53 | +0.16% | 24.9B | 14.72 | $1.75 | +3.84% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
BIO-B vs ABT Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, ABT has a market cap of 181.5B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while ABT trades at $104.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas ABT's P/E ratio is 20.13. In terms of profitability, BIO-B's ROE is +0.03%, compared to ABT's ROE of +0.11%. Regarding short-term risk, BIO-B is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
BIO-B vs BSX-PA Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, BIO-B's ROE is +0.03%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, BIO-B is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check BSX-PA's competition here
Medtronic Plc (NYSE: MDT)
BIO-B vs MDT Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, MDT has a market cap of 121.2B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while MDT trades at $94.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas MDT's P/E ratio is 17.14. In terms of profitability, BIO-B's ROE is +0.03%, compared to MDT's ROE of +0.11%. Regarding short-term risk, BIO-B is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
BIO-B vs SYK Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, SYK has a market cap of 113B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while SYK trades at $295.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas SYK's P/E ratio is 22.01. In terms of profitability, BIO-B's ROE is +0.03%, compared to SYK's ROE of +0.16%. Regarding short-term risk, BIO-B is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
BIO-B vs BSX Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, BSX has a market cap of 64.3B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while BSX trades at $44.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas BSX's P/E ratio is 14.32. In terms of profitability, BIO-B's ROE is +0.03%, compared to BSX's ROE of +0.15%. Regarding short-term risk, BIO-B is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
BIO-B vs EW Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, EW has a market cap of 49.9B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while EW trades at $87.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas EW's P/E ratio is 32.07. In terms of profitability, BIO-B's ROE is +0.03%, compared to EW's ROE of +0.10%. Regarding short-term risk, BIO-B is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
BIO-B vs DXCM Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, DXCM has a market cap of 32.5B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while DXCM trades at $86.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas DXCM's P/E ratio is 33.74. In terms of profitability, BIO-B's ROE is +0.03%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, BIO-B is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
BIO-B vs GEHC Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, GEHC has a market cap of 31.4B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while GEHC trades at $69.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas GEHC's P/E ratio is 15.26. In terms of profitability, BIO-B's ROE is +0.03%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, BIO-B is less volatile compared to GEHC. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
BIO-B vs PHG Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, PHG has a market cap of 24.9B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while PHG trades at $25.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas PHG's P/E ratio is 14.72. In terms of profitability, BIO-B's ROE is +0.03%, compared to PHG's ROE of +0.10%. Regarding short-term risk, BIO-B is less volatile compared to PHG. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
BIO-B vs ZBH Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, ZBH has a market cap of 18.1B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while ZBH trades at $95.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas ZBH's P/E ratio is 11.20. In terms of profitability, BIO-B's ROE is +0.03%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, BIO-B is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
BIO-B vs ABMD Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas ABMD's P/E ratio is 65.36. In terms of profitability, BIO-B's ROE is +0.03%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, BIO-B is less volatile compared to ABMD. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
BIO-B vs PEN Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while PEN trades at $320.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas PEN's P/E ratio is 83.79. In terms of profitability, BIO-B's ROE is +0.03%, compared to PEN's ROE of +0.11%. Regarding short-term risk, BIO-B is less volatile compared to PEN. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
BIO-B vs SWAV Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas SWAV's P/E ratio is 78.76. In terms of profitability, BIO-B's ROE is +0.03%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, BIO-B is less volatile compared to SWAV. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
BIO-B vs SNN Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, SNN has a market cap of 12.2B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while SNN trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas SNN's P/E ratio is 19.62. In terms of profitability, BIO-B's ROE is +0.03%, compared to SNN's ROE of +0.12%. Regarding short-term risk, BIO-B is less volatile compared to SNN. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
BIO-B vs ALGN Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, ALGN has a market cap of 10.5B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while ALGN trades at $147.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas ALGN's P/E ratio is 13.43. In terms of profitability, BIO-B's ROE is +0.03%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, BIO-B is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
BIO-B vs GMED Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, GMED has a market cap of 10.3B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while GMED trades at $76.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas GMED's P/E ratio is 17.27. In terms of profitability, BIO-B's ROE is +0.03%, compared to GMED's ROE of +0.12%. Regarding short-term risk, BIO-B is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check GMED's competition here
Insulet Corp. (NASDAQ: PODD)
BIO-B vs PODD Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, PODD has a market cap of 9.8B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while PODD trades at $140.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas PODD's P/E ratio is 24.04. In terms of profitability, BIO-B's ROE is +0.03%, compared to PODD's ROE of +0.27%. Regarding short-term risk, BIO-B is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check PODD's competition here
Glaukos Corporation (NYSE: GKOS)
BIO-B vs GKOS Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, GKOS has a market cap of 9.7B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while GKOS trades at $167.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas GKOS's P/E ratio is -191.66. In terms of profitability, BIO-B's ROE is +0.03%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, BIO-B is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check GKOS's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
BIO-B vs BIO Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, BIO has a market cap of 9.5B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while BIO trades at $355.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas BIO's P/E ratio is 38.12. In terms of profitability, BIO-B's ROE is +0.03%, compared to BIO's ROE of +0.03%. Regarding short-term risk, BIO-B is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check BIO's competition here
Masimo Corporation (NASDAQ: MASI)
BIO-B vs MASI Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas MASI's P/E ratio is 44.43. In terms of profitability, BIO-B's ROE is +0.03%, compared to MASI's ROE of +0.09%. Regarding short-term risk, BIO-B is similarly volatile compared to MASI. This indicates similar risk in terms of short-term price fluctuations for BIO-B.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
BIO-B vs BRKR Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, BRKR has a market cap of 8.3B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while BRKR trades at $55.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas BRKR's P/E ratio is 27.54. In terms of profitability, BIO-B's ROE is +0.03%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, BIO-B is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
BIO-B vs BRKRP Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, BRKRP has a market cap of 8.3B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while BRKRP trades at $405.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas BRKRP's P/E ratio is 220.46. In terms of profitability, BIO-B's ROE is +0.03%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, BIO-B is less volatile compared to BRKRP. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check BRKRP's competition here
Haemonetics Corporation (NYSE: HAE)
BIO-B vs HAE Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, HAE has a market cap of 5.4B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while HAE trades at $118.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas HAE's P/E ratio is 23.62. In terms of profitability, BIO-B's ROE is +0.03%, compared to HAE's ROE of +0.11%. Regarding short-term risk, BIO-B is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
BIO-B vs NARI Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas NARI's P/E ratio is -59.24. In terms of profitability, BIO-B's ROE is +0.03%, compared to NARI's ROE of -0.00%. Regarding short-term risk, BIO-B is less volatile compared to NARI. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
BIO-B vs ITGR Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while ITGR trades at $126.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas ITGR's P/E ratio is 19.96. In terms of profitability, BIO-B's ROE is +0.03%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, BIO-B is less volatile compared to ITGR. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check ITGR's competition here
LivaNova PLC (NASDAQ: LIVN)
BIO-B vs LIVN Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, LIVN has a market cap of 4.3B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while LIVN trades at $78.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas LIVN's P/E ratio is 18.43. In terms of profitability, BIO-B's ROE is +0.03%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, BIO-B is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check LIVN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
BIO-B vs IRTC Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, IRTC has a market cap of 3.6B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while IRTC trades at $108.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas IRTC's P/E ratio is -252.70. In terms of profitability, BIO-B's ROE is +0.03%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, BIO-B is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check IRTC's competition here
Neogen Corporation (NASDAQ: NEOG)
BIO-B vs NEOG Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while NEOG trades at $11.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas NEOG's P/E ratio is 42.18. In terms of profitability, BIO-B's ROE is +0.03%, compared to NEOG's ROE of -0.03%. Regarding short-term risk, BIO-B is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check NEOG's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
BIO-B vs TMDX Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, TMDX has a market cap of 2.5B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while TMDX trades at $71.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas TMDX's P/E ratio is 35.93. In terms of profitability, BIO-B's ROE is +0.03%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, BIO-B is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check TMDX's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
BIO-B vs UFPT Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while UFPT trades at $292.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas UFPT's P/E ratio is 29.79. In terms of profitability, BIO-B's ROE is +0.03%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, BIO-B is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check UFPT's competition here
NuVasive, Inc. (NASDAQ: NUVA)
BIO-B vs NUVA Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas NUVA's P/E ratio is 75.00. In terms of profitability, BIO-B's ROE is +0.03%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, BIO-B is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check NUVA's competition here
AxoGen, Inc. (NASDAQ: AXGN)
BIO-B vs AXGN Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, AXGN has a market cap of 2B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while AXGN trades at $35.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas AXGN's P/E ratio is 91.13. In terms of profitability, BIO-B's ROE is +0.03%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, BIO-B is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check AXGN's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
BIO-B vs INSP Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, INSP has a market cap of 2B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while INSP trades at $69.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas INSP's P/E ratio is 30.30. In terms of profitability, BIO-B's ROE is +0.03%, compared to INSP's ROE of +0.18%. Regarding short-term risk, BIO-B is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check INSP's competition here
Butterfly Network, Inc. (NYSE: BFLY)
BIO-B vs BFLY Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, BFLY has a market cap of 1.9B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while BFLY trades at $7.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas BFLY's P/E ratio is -30.21. In terms of profitability, BIO-B's ROE is +0.03%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, BIO-B is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check BFLY's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
BIO-B vs ESTA Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, ESTA has a market cap of 1.8B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while ESTA trades at $60.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas ESTA's P/E ratio is -46.96. In terms of profitability, BIO-B's ROE is +0.03%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, BIO-B is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
BIO-B vs NVCR Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, NVCR has a market cap of 1.6B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while NVCR trades at $14.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas NVCR's P/E ratio is -10.82. In terms of profitability, BIO-B's ROE is +0.03%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, BIO-B is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check NVCR's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
BIO-B vs ATEC Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while ATEC trades at $10.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas ATEC's P/E ratio is -174.33. In terms of profitability, BIO-B's ROE is +0.03%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, BIO-B is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check ATEC's competition here
CONMED Corporation (NYSE: CNMD)
BIO-B vs CNMD Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while CNMD trades at $47.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas CNMD's P/E ratio is 10.27. In terms of profitability, BIO-B's ROE is +0.03%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, BIO-B is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check CNMD's competition here
Picard Medical, Inc. (AMEX: PMI)
BIO-B vs PMI Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, PMI has a market cap of 1.3B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while PMI trades at $12.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas PMI's P/E ratio is -10.70. In terms of profitability, BIO-B's ROE is +0.03%, compared to PMI's ROE of -9.31%. Regarding short-term risk, BIO-B is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check PMI's competition here
Heska Corporation (NASDAQ: HSKA)
BIO-B vs HSKA Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas HSKA's P/E ratio is -62.49. In terms of profitability, BIO-B's ROE is +0.03%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, BIO-B is similarly volatile compared to HSKA. This indicates similar risk in terms of short-term price fluctuations for BIO-B.Check HSKA's competition here
Avanos Medical, Inc. (NYSE: AVNS)
BIO-B vs AVNS Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas AVNS's P/E ratio is 27.77. In terms of profitability, BIO-B's ROE is +0.03%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, BIO-B is less volatile compared to AVNS. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check AVNS's competition here
Enovis Corporation (NYSE: ENOV)
BIO-B vs ENOV Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while ENOV trades at $19.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas ENOV's P/E ratio is 5.62. In terms of profitability, BIO-B's ROE is +0.03%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, BIO-B is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check ENOV's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
BIO-B vs TNDM Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while TNDM trades at $16.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas TNDM's P/E ratio is -17.46. In terms of profitability, BIO-B's ROE is +0.03%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, BIO-B is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check TNDM's competition here
IRadimed Corporation (NASDAQ: IRMD)
BIO-B vs IRMD Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while IRMD trades at $89.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas IRMD's P/E ratio is 44.36. In terms of profitability, BIO-B's ROE is +0.03%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, BIO-B is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check IRMD's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
BIO-B vs SILK Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas SILK's P/E ratio is -18.96. In terms of profitability, BIO-B's ROE is +0.03%, compared to SILK's ROE of -0.35%. Regarding short-term risk, BIO-B is less volatile compared to SILK. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
BIO-B vs FNA Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas FNA's P/E ratio is -19.83. In terms of profitability, BIO-B's ROE is +0.03%, compared to FNA's ROE of -0.35%. Regarding short-term risk, BIO-B is less volatile compared to FNA. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check FNA's competition here
Artivion, Inc. (NYSE: AORT)
BIO-B vs AORT Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while AORT trades at $21.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas AORT's P/E ratio is 36.28. In terms of profitability, BIO-B's ROE is +0.03%, compared to AORT's ROE of -0.01%. Regarding short-term risk, BIO-B is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check AORT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
BIO-B vs LMRI Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, LMRI has a market cap of 1B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while LMRI trades at $10.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas LMRI's P/E ratio is -20.99. In terms of profitability, BIO-B's ROE is +0.03%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, BIO-B is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check LMRI's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
BIO-B vs IART Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, IART has a market cap of 1B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while IART trades at $13.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas IART's P/E ratio is 5.60. In terms of profitability, BIO-B's ROE is +0.03%, compared to IART's ROE of -0.01%. Regarding short-term risk, BIO-B is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check IART's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
BIO-B vs PRCT Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, PRCT has a market cap of 1B. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while PRCT trades at $17.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas PRCT's P/E ratio is -9.06. In terms of profitability, BIO-B's ROE is +0.03%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, BIO-B is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check PRCT's competition here
CeriBell, Inc. (NASDAQ: CBLL)
BIO-B vs CBLL Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, CBLL has a market cap of 960.8M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while CBLL trades at $25.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas CBLL's P/E ratio is -14.22. In terms of profitability, BIO-B's ROE is +0.03%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, BIO-B is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check CBLL's competition here
Bioventus Inc. (NASDAQ: BVS)
BIO-B vs BVS Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, BVS has a market cap of 909.5M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while BVS trades at $13.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas BVS's P/E ratio is 17.52. In terms of profitability, BIO-B's ROE is +0.03%, compared to BVS's ROE of +0.28%. Regarding short-term risk, BIO-B is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check BVS's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
BIO-B vs SIBN Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, SIBN has a market cap of 882M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while SIBN trades at $19.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas SIBN's P/E ratio is -57.88. In terms of profitability, BIO-B's ROE is +0.03%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, BIO-B is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check SIBN's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
BIO-B vs CSII Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas CSII's P/E ratio is -20.83. In terms of profitability, BIO-B's ROE is +0.03%, compared to CSII's ROE of -0.14%. Regarding short-term risk, BIO-B is less volatile compared to CSII. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check CSII's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
BIO-B vs AHCO Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, AHCO has a market cap of 820.8M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while AHCO trades at $5.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas AHCO's P/E ratio is 12.29. In terms of profitability, BIO-B's ROE is +0.03%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, BIO-B is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check AHCO's competition here
InMode Ltd. (NASDAQ: INMD)
BIO-B vs INMD Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, INMD has a market cap of 814.8M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while INMD trades at $14.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas INMD's P/E ratio is 9.83. In terms of profitability, BIO-B's ROE is +0.03%, compared to INMD's ROE of +0.12%. Regarding short-term risk, BIO-B is less volatile compared to INMD. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check INMD's competition here
Varex Imaging Corporation (NASDAQ: VREX)
BIO-B vs VREX Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, VREX has a market cap of 781.8M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while VREX trades at $18.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas VREX's P/E ratio is 19.38. In terms of profitability, BIO-B's ROE is +0.03%, compared to VREX's ROE of +0.05%. Regarding short-term risk, BIO-B is less volatile compared to VREX. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check VREX's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
BIO-B vs BBNX Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, BBNX has a market cap of 737.4M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while BBNX trades at $16.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas BBNX's P/E ratio is -9.93. In terms of profitability, BIO-B's ROE is +0.03%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, BIO-B is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check BBNX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
BIO-B vs CTKB Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, CTKB has a market cap of 682.4M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while CTKB trades at $5.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas CTKB's P/E ratio is -27.81. In terms of profitability, BIO-B's ROE is +0.03%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, BIO-B is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check CTKB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
BIO-B vs SRDX Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas SRDX's P/E ratio is -34.66. In terms of profitability, BIO-B's ROE is +0.03%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, BIO-B is similarly volatile compared to SRDX. This indicates similar risk in terms of short-term price fluctuations for BIO-B.Check SRDX's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
BIO-B vs AVR Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, AVR has a market cap of 589.6M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while AVR trades at $6.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas AVR's P/E ratio is -3.12. In terms of profitability, BIO-B's ROE is +0.03%, compared to AVR's ROE of -0.78%. Regarding short-term risk, BIO-B is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check AVR's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
BIO-B vs APEN Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas APEN's P/E ratio is -9.43. In terms of profitability, BIO-B's ROE is +0.03%, compared to APEN's ROE of -0.85%. Regarding short-term risk, BIO-B is less volatile compared to APEN. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check APEN's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
BIO-B vs KIDS Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, KIDS has a market cap of 571.8M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while KIDS trades at $21.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas KIDS's P/E ratio is -18.56. In terms of profitability, BIO-B's ROE is +0.03%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, BIO-B is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check KIDS's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
BIO-B vs PACB Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, PACB has a market cap of 537.7M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while PACB trades at $1.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas PACB's P/E ratio is -4.22. In terms of profitability, BIO-B's ROE is +0.03%, compared to PACB's ROE of -49.62%. Regarding short-term risk, BIO-B is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check PACB's competition here
ZimVie Inc. (NASDAQ: ZIMV)
BIO-B vs ZIMV Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, BIO-B's ROE is +0.03%, compared to ZIMV's ROE of -0.07%. Regarding short-term risk, BIO-B is similarly volatile compared to ZIMV. This indicates similar risk in terms of short-term price fluctuations for BIO-B.Check ZIMV's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
BIO-B vs TCMD Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, TCMD has a market cap of 510.1M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while TCMD trades at $22.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas TCMD's P/E ratio is 20.85. In terms of profitability, BIO-B's ROE is +0.03%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, BIO-B is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check TCMD's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
BIO-B vs SSII Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, SSII has a market cap of 507.2M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while SSII trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas SSII's P/E ratio is -42.17. In terms of profitability, BIO-B's ROE is +0.03%, compared to SSII's ROE of -0.27%. Regarding short-term risk, BIO-B is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check SSII's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
BIO-B vs DCTH Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, DCTH has a market cap of 488.4M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while DCTH trades at $14.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas DCTH's P/E ratio is 1407.50. In terms of profitability, BIO-B's ROE is +0.03%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, BIO-B is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check DCTH's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
BIO-B vs SGHT Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, SGHT has a market cap of 456.1M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while SGHT trades at $8.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas SGHT's P/E ratio is -14.79. In terms of profitability, BIO-B's ROE is +0.03%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, BIO-B is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check SGHT's competition here
Cerus Corporation (NASDAQ: CERS)
BIO-B vs CERS Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, CERS has a market cap of 437.3M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while CERS trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas CERS's P/E ratio is -72.09. In terms of profitability, BIO-B's ROE is +0.03%, compared to CERS's ROE of -0.10%. Regarding short-term risk, BIO-B is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
BIO-B vs NPCE Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, NPCE has a market cap of 420.1M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while NPCE trades at $12.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas NPCE's P/E ratio is -21.47. In terms of profitability, BIO-B's ROE is +0.03%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, BIO-B is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check NPCE's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
BIO-B vs SENS Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, SENS has a market cap of 410.8M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while SENS trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas SENS's P/E ratio is -3.48. In terms of profitability, BIO-B's ROE is +0.03%, compared to SENS's ROE of -1.66%. Regarding short-term risk, BIO-B is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
BIO-B vs OFIX Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, OFIX has a market cap of 379.2M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while OFIX trades at $9.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas OFIX's P/E ratio is -6.11. In terms of profitability, BIO-B's ROE is +0.03%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, BIO-B is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check OFIX's competition here
CapsoVision, Inc. (NASDAQ: CV)
BIO-B vs CV Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, CV has a market cap of 347.5M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while CV trades at $6.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas CV's P/E ratio is -10.37. In terms of profitability, BIO-B's ROE is +0.03%, compared to CV's ROE of -1.78%. Regarding short-term risk, BIO-B is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check CV's competition here
Avita Medical Inc. (NASDAQ: RCEL)
BIO-B vs RCEL Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, RCEL has a market cap of 324M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while RCEL trades at $13.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas RCEL's P/E ratio is -9.06. In terms of profitability, BIO-B's ROE is +0.03%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, BIO-B is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check RCEL's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
BIO-B vs SMLR Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas SMLR's P/E ratio is 3.92. In terms of profitability, BIO-B's ROE is +0.03%, compared to SMLR's ROE of +0.20%. Regarding short-term risk, BIO-B is similarly volatile compared to SMLR. This indicates similar risk in terms of short-term price fluctuations for BIO-B.Check SMLR's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
BIO-B vs CLPT Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, CLPT has a market cap of 276.7M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while CLPT trades at $9.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas CLPT's P/E ratio is -7.69. In terms of profitability, BIO-B's ROE is +0.03%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, BIO-B is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check CLPT's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
BIO-B vs INFU Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, INFU has a market cap of 266.9M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while INFU trades at $13.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas INFU's P/E ratio is 32.68. In terms of profitability, BIO-B's ROE is +0.03%, compared to INFU's ROE of +0.15%. Regarding short-term risk, BIO-B is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check INFU's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
BIO-B vs TMCI Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, TMCI has a market cap of 251.7M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while TMCI trades at $3.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas TMCI's P/E ratio is -4.12. In terms of profitability, BIO-B's ROE is +0.03%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, BIO-B is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check TMCI's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
BIO-B vs CATX Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, CATX has a market cap of 247.7M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while CATX trades at $2.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas CATX's P/E ratio is -1.63. In terms of profitability, BIO-B's ROE is +0.03%, compared to CATX's ROE of -0.42%. Regarding short-term risk, BIO-B is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check CATX's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
BIO-B vs MGRM Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas MGRM's P/E ratio is -12.00. In terms of profitability, BIO-B's ROE is +0.03%, compared to MGRM's ROE of -1.17%. Regarding short-term risk, BIO-B is similarly volatile compared to MGRM. This indicates similar risk in terms of short-term price fluctuations for BIO-B.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
BIO-B vs ELMD Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, ELMD has a market cap of 228.1M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while ELMD trades at $27.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas ELMD's P/E ratio is 21.02. In terms of profitability, BIO-B's ROE is +0.03%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, BIO-B is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
BIO-B vs NVRO Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas NVRO's P/E ratio is -1.91. In terms of profitability, BIO-B's ROE is +0.03%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, BIO-B is less volatile compared to NVRO. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check NVRO's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
BIO-B vs TLSI Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, TLSI has a market cap of 223.5M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while TLSI trades at $3.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas TLSI's P/E ratio is -2.16. In terms of profitability, BIO-B's ROE is +0.03%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, BIO-B is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check TLSI's competition here
Quantum-Si incorporated (NASDAQ: QSI)
BIO-B vs QSI Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, QSI has a market cap of 222.8M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while QSI trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas QSI's P/E ratio is -2.43. In terms of profitability, BIO-B's ROE is +0.03%, compared to QSI's ROE of -0.47%. Regarding short-term risk, BIO-B is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check QSI's competition here
Profound Medical Corp. (NASDAQ: PROF)
BIO-B vs PROF Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, PROF has a market cap of 219.6M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while PROF trades at $6.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas PROF's P/E ratio is -6.13. In terms of profitability, BIO-B's ROE is +0.03%, compared to PROF's ROE of -0.56%. Regarding short-term risk, BIO-B is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check PROF's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
BIO-B vs BSGM Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas BSGM's P/E ratio is -5.81. In terms of profitability, BIO-B's ROE is +0.03%, compared to BSGM's ROE of +6.96%. Regarding short-term risk, BIO-B is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check BSGM's competition here
RxSight, Inc. (NASDAQ: RXST)
BIO-B vs RXST Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, RXST has a market cap of 187.6M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while RXST trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas RXST's P/E ratio is -3.99. In terms of profitability, BIO-B's ROE is +0.03%, compared to RXST's ROE of -0.17%. Regarding short-term risk, BIO-B is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check RXST's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
BIO-B vs MDGS Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas MDGS's P/E ratio is -0.27. In terms of profitability, BIO-B's ROE is +0.03%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, BIO-B is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check MDGS's competition here
Inogen, Inc. (NASDAQ: INGN)
BIO-B vs INGN Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, INGN has a market cap of 165.9M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while INGN trades at $6.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas INGN's P/E ratio is -6.87. In terms of profitability, BIO-B's ROE is +0.03%, compared to INGN's ROE of -0.13%. Regarding short-term risk, BIO-B is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check INGN's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
BIO-B vs QIPT Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas QIPT's P/E ratio is -15.87. In terms of profitability, BIO-B's ROE is +0.03%, compared to QIPT's ROE of -0.08%. Regarding short-term risk, BIO-B is similarly volatile compared to QIPT. This indicates similar risk in terms of short-term price fluctuations for BIO-B.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
BIO-B vs FOCL Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, FOCL has a market cap of 154.8M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while FOCL trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas FOCL's P/E ratio is -3.99. In terms of profitability, BIO-B's ROE is +0.03%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, BIO-B is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check FOCL's competition here
Neuronetics, Inc. (NASDAQ: STIM)
BIO-B vs STIM Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, STIM has a market cap of 143.6M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while STIM trades at $1.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas STIM's P/E ratio is -4.28. In terms of profitability, BIO-B's ROE is +0.03%, compared to STIM's ROE of -1.51%. Regarding short-term risk, BIO-B is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check STIM's competition here
Quanterix Corporation (NASDAQ: QTRX)
BIO-B vs QTRX Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, QTRX has a market cap of 135.7M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while QTRX trades at $2.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas QTRX's P/E ratio is -1.13. In terms of profitability, BIO-B's ROE is +0.03%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, BIO-B is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check QTRX's competition here
Owlet, Inc. (NYSE: OWLT)
BIO-B vs OWLT Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, OWLT has a market cap of 120.1M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while OWLT trades at $4.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas OWLT's P/E ratio is -29.36. In terms of profitability, BIO-B's ROE is +0.03%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, BIO-B is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check OWLT's competition here
iCAD, Inc. (NASDAQ: ICAD)
BIO-B vs ICAD Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas ICAD's P/E ratio is -20.37. In terms of profitability, BIO-B's ROE is +0.03%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, BIO-B is similarly volatile compared to ICAD. This indicates similar risk in terms of short-term price fluctuations for BIO-B.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
BIO-B vs HJLI Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas HJLI's P/E ratio is N/A. In terms of profitability, BIO-B's ROE is +0.03%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, BIO-B is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
BIO-B vs ASXC Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas ASXC's P/E ratio is -1.12. In terms of profitability, BIO-B's ROE is +0.03%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, BIO-B is less volatile compared to ASXC. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check ASXC's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
BIO-B vs LUCD Comparison October 2026
Bio-Rad Laboratories, Inc. (NYSE: BIO-B) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIO-B stands at 9.6B. In comparison, LUCD has a market cap of 91.3M. Regarding current trading prices, BIO-B is priced at $355.39 on the NYSE, while LUCD trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIO-B currently has a P/E ratio of -62.58, whereas LUCD's P/E ratio is -1.29. In terms of profitability, BIO-B's ROE is +0.03%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, BIO-B is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for BIO-B.Check LUCD's competition here